Medical and hoarse bottles are seen with the Novo Nordisk logo on a background screen.
Norfuto Norfuto Gety pictures
Novo NordskThe hopes of the seed in a new era of treating obesity with its drug in its complexities were asked after a series of results of the trial that sent the shares.
Address results from the RideFine-2 experience late in the stage Absolute Earlier this month, it showed that the complexity of the kagima from the next generation of Novo helped adult patients with obese or overweight overweight patients with type 2 15.7 % of their weight over 68 weeks, compared to 3.1 % with a placebo. This was less than the high -loss percentage of weight loss.
Previous trial late in the stage Published In December, it showed that the drug helped patients with obese or overweight with one or more accompanying patients, but not type 2 diabetes, their weight reduces 22.7 % after 68 weeks, or less than 25 % expected.
The two results have wiped a large value of the price of the Novo share as the hope of investors to find a superior alternative to the current Wegovy injection and the competition ELI Lily’s Zebound, both GLP-1, edited.
The beloved inventory decreased once about 50 % of its highest levels in 2024.
“Feelings towards these men are negative as they were before,” Emily Field, head of European pharmaceutical research at Barclays, told CNBC on Wednesday.
Novo Nordsk
“The share of the stock reaction is not proportional, but there are no buyers who belong to the sellers,” Field said, noting that some American hedge funds are now limiting the shares, either because of the experimental results or more of the concerns related to high rates in the drug loss industry.
Obesity treatment of the next generation
CAGRISEMA is a mixture of declaring dandruff – an emerging form of weighing loss known as analog amylene – and gmuutide, the active ingredient in Wegovy.
It was hoped that the drug would provide improved weight loss for patients with diabetes, who usually have more difficult time to get rid of current GLP-1 treatments, but weight reduction by 15.7 % of the REDEFINE-2 trial is disappointed.
“We have seen the possibility to show my advertisement in showing the superior weight loss in Zepbound due to the amylan component; however, the complications of obesity from obesity to obese patients seem to be very similar to both Sepa and Zepbbound,”
There is a very short -term focus at the present time. People only do not think about the broader capabilities.
Emily Field
Head of European Pharmaceutical Research in Barclays
Meanwhile, the questions about the endurance remain for Kagima, with less than two thirds of patients to the top of the dose after 68 weeks. Novo said last week that Cagersima was “well calculated” and that the most common harmful effects were intestinal, but it was “moderate to moderate and decreased over time.”
“Investors are looking for better treatment options in the class and they will secure the location of Novo in the obesity drug market,” Surin Luntutet, Sidbank’s stock analyst, told CNBC on Tuesday. “We are not sure that Cagrisma is the best in the chapter.”
However, the upcoming REDEFINE-4 study, due to its release in early 2026, can provide more colors on the effectiveness of the drug over a long-term period and more flexible doses-something he said Lontoft can distinguish it.
“This can be caused by excellence,” said Luntutet.
Expanding weight loss treatments
The weight loss industry is still divided into the broader applications and the results of obesity drugs exceeding weight reduction. In a separate note last week, Bofa said it has grown “a little more cautious about differentiation” in the treatment of obesity and diabetes after the latest CAGRISEMA results.
“There is a very short -term focus at the moment. People are not thinking about the wider capabilities,” Field.
However, LONOFT indicated the need for a variety of treatments to treat both obesity and associated health risks, such as cardiovascular diseases, sleep breathing and liver disease – areas where medicines already show them they are Make progress.
“It is about meeting the various needs in this market,” he said. He said, “The companies that are able to meet these different needs are better – in conjunction with great production capabilities – take the largest part of this market,” he said.
Other companies hope to participate in the market, which is worth $ 100 billion by 2030. Earlier this month, the Swiss drug giant Rush A deal worth up to $ 5.3 billion to develop Danish biotechnology Zealand Pharma‘s Analog Obesity drug candidate.
Investors and patients will have to wait at some point until these products are launched, with the CEO of Zealand Pharma and President Adam Steinsburg Saying CNBC, who is expected to come to the market around 2030. At the same time, Novo Nordisk said, he expects to provide regulatory approval on Cagrisema in the first quarter of 2026.
However, the company has a way to go to recover some of the previous noise around the drug. When asked if the investors would get to know it as one of several possible heavyweight alternatives, Surin was cautious: “No. But I think they will do in the end.”
https://image.cnbcfm.com/api/v1/image/108096178-1738569795714-gettyimages-1244663026-porzycki-pharmace221110_npYhk.jpeg?v=1741609523&w=1920&h=1080
Source link